'Other than some amazing revenue figures flowing from Elixia,...

'Other than some amazing revenue figures flowing from Elixia, ENA and other new revenue producing additions, I can't see a major price rise until it becomes clearer that a pain portfolio deal is nearing reality.' (makattack)

An excellent summary, mak. Whatever the explanation for the latest procrastination (thanks the excellent posts, jev & southoz) POH seem to have reverted to veering from one strategy to another and they now have decided to

'convene a medical advisory panel as soon as possible to prioritise the pain indication it will pursue first for the TPM/oxycodone patch'

The explanation given seems to be that recent work has opened up vistas of whole new worlds to conquer. Very well. But to the lay mind, you would have thought they would have had at least some idea of a target in the work/trials to date. Why not bash on as planned in 2013 & prove the patch for the application originally envisaged? A solid proof of the application & potential early cash generator. The others could be identified in parallel and worked up next year.

H1 2014 is very vague. On that basis, it could be nearly another year before stage 2 trials begin. Meanwhile the cash pile diminishes.

It does make you wonder... Ah well! Back to sleep.